Immunobiome participates in 'FIMSA 2021'... "Actively pursuing talent discovery"

[Asia Economy Reporter Hyunseok Yoo] Immunobiome, a microbiome-based new drug research and development company, announced on the 29th that it will participate in 'FIMSA 2021 (Federation of Immunological Societies of Asia-Oceania)' held in Busan for four days starting from the 31st.

'FIMSA 2021' is an international academic conference organized by the non-profit organization FIMSA, established in 1992 for the advancement of immunology in the Asia-Pacific region, marking its 8th event this year. This conference promotes exchange among immunology societies in Asia and Oceania, provides opportunities for sharing scientific information, and discovers talented individuals.

A company official stated, “Immunobiome has discovered strains that enhance immunity or induce hypersensitivity suppression, and holds numerous domestic and international patents by identifying effective active substances and efficacies derived from these microorganisms. Currently, we are discovering microorganisms for immune disease treatment and various therapeutic candidates and are conducting clinical trials. Based on this, we plan to commercialize microbiome new drugs.”

At this event, Immunobiome plans to participate in academic presentations and the accompanying job fair to introduce the company directly on-site and recruit talent.

The official added, “Ahead of the planned initial public offering (IPO) in 2023, we will hire more than 20 experienced employees across all departments including research and development, business development, and management.”

For the research and development department, the positions include ▲ research planning and support ▲ development of anticancer and anti-inflammatory agents ▲ microbial culture and analysis. They are looking for senior to principal researchers with majors in life sciences and at least 3 to 4 years of relevant experience. The main workplace is the headquarters located within Pohang University of Science and Technology (POSTECH), and to attract talent nationwide including the Seoul metropolitan area, they plan to operate an exceptional remote work support system for key positions such as team leaders.

Other departments have their main workplace at the Seoul office. For business development, the roles include ▲ market and technology trend analysis ▲ planning and execution of license in/out ▲ clinical development and management ▲ patent strategy and management. Candidates with majors in medicine and life sciences and experience at assistant manager to department head level are sought. Preference is given to those with experience at global big pharma and major domestic pharmaceutical companies. The management department roles include ▲ strategic planning ▲ public relations ▲ investor relations (IR), also hiring at assistant manager to department head level.

An Immunobiome HR representative said, “Final successful candidates will be offered stock options and benefits to share in the joy of the company’s growth.”

The Immunobiome recruitment schedule may change depending on company circumstances, and applications are accepted through the company website or via the recruitment manager’s email. Additionally, recruitment consultations and resume submissions will be conducted through the job fair held at 'FIMSA 2021'.

This content was produced with the assistance of AI translation services.